Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ONCY

Oncolytics Biotech, Inc

Dec 11 • 04:00PM ET

0.8537

Dollar change -0.0053
Percentage change -0.62	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	1.40%	Shs Outstand	77.07M	Perf Week	-3.21%
Market Cap	65.79M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	75.99M	Perf Month	-20.95%
Income	-20.31M	PEG	-	EPS next Q	-0.08	Inst Own	1.62%	Short Float	3.49%	Perf Quarter	-10.95%
Sales	0.00M	P/S	-	EPS this Y	-0.20%	Inst Trans	-6.70%	Short Ratio	5.45	Perf Half Y	-17.12%
Book/sh	0.09	P/B	9.81	EPS next Y	-7.02%	ROA	-78.05%	Short Interest	2.65M	Perf Year	-34.83%
Cash/sh	0.19	P/C	4.53	EPS next 5Y	-	ROE	-144.22%	52W Range	0.84 - 1.53	Perf YTD	-36.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.01%	ROI	-278.00%	52W High	-44.20%	Beta	1.30
Dividend TTM	-	Quick Ratio	2.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.62%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.99	EPS Y/Y TTM	28.43%	Oper. Margin	-	RSI (14)	31.69	Volatility	4.47% 5.80%
Employees	27	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	4.93
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	14.34%	Payout	-	Rel Volume	1.01	Prev Close	0.86
Sales Surprise	-	EPS Surprise	-16.98%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	486.10K	Price	0.85
SMA20	-9.02%	SMA50	-21.42%	SMA200	-18.46%	Trades		Volume	489,915	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Dec-03-24 07:00AM	Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort (PR Newswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 02:08AM	Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -8.04%
Nov-12-24 07:00AM	Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
07:00AM	Loading…
Nov-11-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire) +7.83%
Oct-07-24 11:21AM	Oncolytics targets accelerated approval for oncolytic virus therapy (Pharmaceutical Technology) +27.27%
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +18.22%
07:00AM	Oncolytics Biotech Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path (PR Newswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
09:00AM	How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
07:00AM	Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study (PR Newswire)
08:00AM	Loading…
Sep-06-24 08:00AM	Oncolytics Biotech to Participate in Fireside Chats at Two Investment Conferences in September (PR Newswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:45AM	Sernova Corp. Announces Appointment of New Chief Executive Officer (GlobeNewswire)
Aug-02-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference (PR Newswire)
Aug-01-24 04:01PM	Oncolytics Biotech Reports Second Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
Jul-24-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
07:00AM	Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program (PR Newswire)
Jun-24-24 07:00AM	Oncolytics Biotech Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence (PR Newswire)
Jun-21-24 06:53AM	Oncolytics doses first subject in pancreatic cancer trial (Clinical Trials Arena)
Jun-20-24 05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
07:26AM	Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer (PR Newswire)
Jun-19-24 01:09PM	From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data (PR Newswire)
10:22AM	Loading…
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 09:55AM	Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-24-24 12:16PM	Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More (PR Newswire)
08:45AM	Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 (GlobeNewswire)
07:00AM	Oncolytics Biotech ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action (PR Newswire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-16-24 07:00AM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
08:03AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial (MT Newswires)
07:00AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial (PR Newswire)
May-10-24 04:35PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.65%
May-09-24 08:59PM	ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024 (InvestorPlace) +5.08%
04:21PM	Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million (MT Newswires)
04:01PM	Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
08:08AM	Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer (MT Newswires)
07:00AM	Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer (PR Newswire)
May-08-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Apr-25-24 07:00AM	Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-11-24 09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
07:00AM	Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA (PR Newswire)
Apr-02-24 07:00AM	Oncolytics Biotech to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference (PR Newswire)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-10-24 08:36AM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:55PM	ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (PR Newswire)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 08:30AM	Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) +11.96%
07:00AM	Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN (PR Newswire)
Mar-04-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire) -17.86%
Feb-28-24 07:00AM	Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference (PR Newswire)
Feb-15-24 08:00AM	Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments (Newsfile)
Feb-14-24 08:30AM	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies (GlobeNewswire) +9.52%
07:00AM	Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort (PR Newswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire) -14.94%
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire) -8.82%
07:00AM	Oncolytics Biotech Appoints Patricia S. Andrews to its Board of Directors (PR Newswire)
Jan-04-24 07:00AM	Oncolytics Biotech Recaps 2023 Accomplishments, Provides Outlook for 2024 (PR Newswire)
Dec-07-23 07:00AM	Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS (PR Newswire)
Nov-29-23 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-09-23 08:45AM	Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance (PR Newswire) -15.92%
07:00AM	Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy (PR Newswire)
06:30AM	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep (PR Newswire)
Nov-05-23 02:29PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 12:03PM	Oncolytics Biotech and SOLTI Present Further Positive Pelareorep Translational Data at SITC (PR Newswire)
07:00AM	Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Oct-23-23 09:50AM	Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise (PR Newswire) +9.03%
08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
07:05AM	Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO (PR Newswire)
07:00AM	Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study (PR Newswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-16-23 07:00AM	Oncolytics Biotech To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 (PR Newswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-26-23 08:00AM	THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS (PR Newswire)
Sep-19-23 07:00AM	Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference (PR Newswire)
Sep-07-23 09:22AM	Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering (PR Newswire) -5.83%
Sep-06-23 07:00AM	Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-21-23 07:00AM	3 Under-$20 Stocks to Buy for Explosive Returns (InvestorPlace)
Aug-17-23 09:35AM	After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY) (Zacks)
Aug-14-23 07:00AM	Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Aug-08-23 08:50AM	Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs (PR Newswire)

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc

Upgrade your FINVIZ experience